Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains
Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.
Pharma & Biotech
Pharma & Biotech
Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage
Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.